VASTAREL

This brand name is authorized in Austria, Brazil, Cyprus, Ecuador, France, Hong Kong SAR China, Ireland, Japan, Malta, Singapore, Tunisia, Turkey.

Active ingredients

The drug VASTAREL contains one active pharmaceutical ingredient (API):

1	Trimetazidine UNII 48V6723Z1P - TRIMETAZIDINE DIHYDROCHLORIDE
	In patients with ischaemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels.
	Read more about Trimetazidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VASTAREL	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01EB15	Trimetazidine	C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations
Discover more medicines within C01EB15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	531302201116416, 531302202112414, 531320050010407, 531321070011703
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	24.718-09-02, 6211-MEE-0521, 6425-MEE-0721
FR	Base de données publique des médicaments	60269037, 62611660
HK	Department of Health Drug Office	49874, 63019
IE	Health Products Regulatory Authority	55829
JP	医薬品医療機器総合機構	2171007F1210
MT	Medicines Authority	MA066/01001, MA066/01002
SG	Health Sciences Authority	01673P, 12268P
TN	Direction de la Pharmacie et du Médicament	6353061, 9163202, 9253911
TR	İlaç ve Tıbbi Cihaz Kurumu	8699552010326, 8699552090335, 8699552150039, 8699552150046, 8699552150053